Community-Acquired Bacterial Pneumonia
To determine the in-vitro susceptibilities of delafloxacin and the comparator quinolones, the researchers tested clinical isolates from patients with community-acquired pneumonia and lower respiratory tract infections at 67 US-based medical centers that participated in the SENTRY Surveillance Program.
In this podcast, Thomas M. File, Jr, MD, MSc, MACP, talks about his session at CHEST 2021, during which he discussed the results of the LEAP 1 and 2 trials that evaluated the efficacy and safety of lefamulin for treating community-acquired pneumonia.
The study included 637 patients initiated on the pathway at seven SSM Health Wisconsin hospitals between September 1, 2020, and June 30, 2021.
In this podcast, Christian Sandrock, MD, MPH, talks about the burden of community-acquired bacterial pneumonia (CABP) in the United States, including the financial burden, the burden on hospitals, and readmission rates.